Erik Rytting

Dr. Erik Rytting


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2017 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
SASanaalarab Al-Enazy
Sanaalarab Al-Enazy
SAShariq Ali
Shariq Ali
NANorah Albekairi
Norah Albekairi
MEMarwa El-Tawil
Marwa El-Tawil
ERErik Rytting
Erik Rytting

1 September 2013 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
HAHazem Ali
Hazem Ali
IKIrina Kalashnikova
Irina Kalashnikova
Mark Andrew WhiteMark Andrew White
Mark Andrew White
MSMichael Sherman
Michael Sherman
ERErik Rytting
Erik Rytting

1 July 2013 in Nanotoxicology
Verified
Journal Article
Closed access
PDF file
MPMarie Sønnegaard Poulsen
Marie Sønnegaard Poulsen
TMTina Mose
Tina Mose
LMLisa Leth Maroun
Lisa Leth Maroun
LMLine Mathiesen
Line Mathiesen
Lisbeth E. KnudsenLisbeth E. Knudsen
Lisbeth E. Knudsen
ERErik Rytting
Erik Rytting
The potential medical applications of nanoparticles (NPs) warrant their investigation in terms of biodistribution and safety during pregnancy. The transport of silica NPs across the placenta was investigated using two models of maternal–foetal transfer in human placenta, namely, the BeWo b30 choriocarcinoma cell line and the ex vivo perfused human placenta. Nanotoxicity in BeWo cells was examined by the MTT assay which demonstrated decreased cell viability at concentrations >100 µg/mL. In the placental perfusion experiments, antipyrine crossed the placenta rapidly, with a foetal:maternal ratio of 0.97 ± 0.10 after 2 h. In contrast, the percentage of silica NPs reaching the foetal perfusate after 6 h was limited to 4.2 ± 4.9% and 4.6 ± 2.4% for 25 and 50 nm NPs, respectively. The transport of silica NPs across the BeWo cells was also limited, with an apparent permeability of only 1.54 × 10−6 ± 1.56 × 10−6 cm/s. Using confocal microscopy, there was visual confirmation of particle accumulation in both BeWo cells and in perfused placental tissue. Despite the low transfer of silica NPs to the foetal compartment, questions regarding biocompatibility could limit the application of unmodified silica NPs in biomedical imaging or therapy.

1 January 2012 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
LCLaura Cartwright
Laura Cartwright
MPMarie Sønnegaard Poulsen
Marie Sønnegaard Poulsen
HNHanne Morck Nielsen
Hanne Morck Nielsen
GPGiulio Pojana
Giulio Pojana
Lisbeth E. KnudsenLisbeth E. Knudsen
Lisbeth E. Knudsen
ERErik Rytting
Erik Rytting
Background: Advances in biomedical nanotechnology raise hopes in patient populations but may also raise questions regarding biodistribution and biocompatibility, especially during pregnancy. Special consideration must be given to the placenta as a biological barrier because a pregnant woman's exposure to nanoparticles could have significant effects on the fetus developing in the womb. Therefore, the purpose of this study is to optimize an in vitro model for characterizing the transport of nanoparticles across human placental trophoblast cells. Methods: The growth of BeWo (clone b30) human placental choriocarcinoma cells for nanoparticle transport studies was characterized in terms of optimized Transwell® insert type and pore size, the investigation of barrier properties by transmission electron microscopy, tight junction staining, transepithelial electrical resistance, and fluorescein sodium transport. Following the determination of nontoxic concentrations of fluorescent polystyrene nanoparticles, the cellular uptake and transport of 50 nm and 100 nm diameter particles was measured using the in vitro BeWo cell model. Results: Particle size measurements, fluorescence readings, and confocal microscopy indicated both cellular uptake of the fluorescent polystyrene nanoparticles and the transcellular transport of these particles from the apical (maternal) to the basolateral (fetal) compartment. Over the course of 24 hours, the apparent permeability across BeWo cells grown on polycarbonate membranes (3.0 µm pore size) was four times higher for the 50 nm particles compared with the 100 nm particles. Conclusion: The BeWo cell line has been optimized and shown to be a valid in vitro model for studying the transplacental transport of nanoparticles. Fluorescent polystyrene nanoparticle transport was size-dependent, as smaller particles reached the basal (fetal) compartment at a higher rate.

1 March 2015 in International Journal of Nanomedicine
Verified
Journal Article
Open access
ERErik Rytting
Erik Rytting
HAHazem Ali
Hazem Ali
Nunzio DenoraNunzio Denora
Nunzio Denora
Antonio LopalcoAntonio Lopalco
Antonio Lopalco
Encapsulation of antiepileptic drugs (AEDs) into nanoparticles may offer promise for treating pregnant women with epilepsy by improving brain delivery and limiting the transplacental permeability of AEDs to avoid fetal exposure and its consequent undesirable adverse effects. Oxcarbazepine-loaded nanoparticles were prepared by a modified solvent displacement method from biocompatible polymers (poly(lactic-co-glycolic acid) [PLGA] with or without surfactant and PEGylated PLGA [Resomer® RGPd5055]). The physical properties of the developed nanoparticles were determined with subsequent evaluation of their permeability across in vitro models of the blood–brain barrier (hCMEC/D3 cells) and human placental trophoblast cells (BeWo b30 cells). Oxcarbazepine-loaded nanoparticles with encapsulation efficiency above 69% were prepared with sizes ranging from 140–170 nm, polydispersity indices below 0.3, and zeta potential values below −34 mV. Differential scanning calorimetry and X-ray diffraction studies confirmed the amorphous state of the nanoencapsulated drug. The apparent permeability (Pe) values of the free and nanoencapsulated oxcarbazepine were comparable across both cell types, likely due to rapid drug release kinetics. Transport studies using fluorescently-labeled nanoparticles (loaded with coumarin-6) demonstrated increased permeability of surfactant-coated nanoparticles. Future developments in enzyme-prodrug therapy and targeted delivery are expected to provide improved options for pregnant patients with epilepsy.

4 February 2014 in Clinical Pharmacokinetics
Verified
Journal Article
Closed access
PDF file
ERErik Rytting
Erik Rytting
TNTatiana N. Nanovskaya
Tatiana N. Nanovskaya
XWXiaoming Wang
Xiaoming Wang
DVDaria I. Vernikovskaya
Daria I. Vernikovskaya
SCShannon M. Clark
Shannon M. Clark
MAMahmoud S. Ahmed
Mahmoud S. Ahmed